ECCO 2017 | BRAF mutated melanoma: targeted or immunotherapy?
Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of immunotherapy and targeted therapy in melanoma at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. In some melanoma types, such as acral and mucosal, there are fewer BRAF mutations. These therefore do not respond as well to targeted therapy, and immunotherapy is typically used in these cases. For patients with BRAF mutations, there are ongoing clinical trials as to whether immunotherapy or targeted therapy should be used first-line.
Get great new content delivered to your inboxSign up